Kardi Ai raises €5.3M Series A for predictive heart monitoring
What's the deal? Czech medtech Kardi AiDealroom has a profile for this one. Try Dealroom → has raised €5.3 million in a Series A round led by German healthtech fund Callisto Health. The company says it is the largest medtech financing by a Czech startup to date, valuing it at €23 million.
Who else is in? Banks Česká spořitelnaDealroom has a profile for this one. Try Dealroom → and Slovenská sporiteľňa joined through Seed Starter SKDealroom has a profile for this one. Try Dealroom →, alongside returning backers BrightCap VenturesDealroom has a profile for this one. Try Dealroom →, Purple VenturesDealroom has a profile for this one. Try Dealroom →, DEPO VenturesDealroom has a profile for this one. Try Dealroom → and Garage AngelsDealroom has a profile for this one. Try Dealroom →.
What does it do? Kardi Ai pairs a chest strap with a built-in electrocardiogram (ECG) sensor, a mobile app and AI analysis to spot heart rhythm disorders. Worn during everyday activity, it catches intermittent arrhythmias that short clinic check-ups often miss. The system supports physicians rather than diagnosing.
The platform works with more than 70 hospitals in the Czech Republic and serves over 6,000 users. The company says it has flagged possible arrhythmias in roughly a quarter of users, including more than 500 critical findings.
What's the money for? Expansion. Germany is the immediate European target after completed pilots, with planned entries in India, the United Arab Emirates and Singapore. Kardi Ai already operates in Slovakia, Poland, Romania and Bulgaria.
What's the endgame? The company wants to move from detection to prediction, building models that estimate arrhythmia risk before it occurs. "We are gradually moving beyond detecting heart rhythm disorders towards technology capable of identifying an increased risk before arrhythmia manifests," said co-founder and chief executive officer Vlastimil Hrabal.
What could go wrong? Those predictive models remain under development and need clinical validation and regulatory approval before reaching medical practice.
The signal: Investor interest in AI-enabled cardiac monitoring is building — Paris-based Implicity raised €35 million in September for remote monitoring and heart-failure prediction tools. Kardi Ai's success will hinge on proving its predictive technology and turning planned market entries into adoption.
Read more: Tech.eu
Image credit: Kardi AI
